ImmuCell (NASDAQ:ICCC - Get Free Report)'s stock had its "hold (c-)" rating reiterated by stock analysts at Weiss Ratings in a note issued to investors on Wednesday,Weiss Ratings reports.
ImmuCell Price Performance
NASDAQ ICCC opened at $6.59 on Wednesday. ImmuCell has a 12 month low of $3.38 and a 12 month high of $7.60. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.85 and a quick ratio of 1.99. The firm has a market capitalization of $59.64 million, a PE ratio of 34.69 and a beta of 0.30. The company's 50 day simple moving average is $6.22 and its 200 day simple moving average is $6.04.
ImmuCell (NASDAQ:ICCC - Get Free Report) last posted its quarterly earnings data on Thursday, August 14th. The biotechnology company reported $0.06 EPS for the quarter. ImmuCell had a net margin of 6.23% and a return on equity of 6.25%. The business had revenue of $6.45 million for the quarter.
Institutional Inflows and Outflows
An institutional investor recently raised its position in ImmuCell stock. Geode Capital Management LLC boosted its holdings in ImmuCell Corporation (NASDAQ:ICCC - Free Report) by 4.2% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 71,852 shares of the biotechnology company's stock after buying an additional 2,907 shares during the quarter. Geode Capital Management LLC owned 0.79% of ImmuCell worth $500,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 13.47% of the company's stock.
ImmuCell Company Profile
(
Get Free Report)
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider ImmuCell, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmuCell wasn't on the list.
While ImmuCell currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
